SIM
VRTX icon

Sentry Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Sentry Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-640
Closed -$290K – 474
2025
Q4 		$290K Hold
640
– – 0.19% 100
2025
Q3 		$270K Sell
640
-181
-22% -$75.6K 0.18% 108
2025
Q2 		$383K Hold
821
– – 0.21% 104
2025
Q1 		$390K Sell
821
-245
-23% -$114K 0.26% 79
2024
Q4 		$429K Sell
1,066
-174
-14% -$80.7K 0.2% 108
2024
Q3 		$577K Hold
1,240
– – 0.24% 92
2024
Q2 		$581K Sell
1,240
-254
-17% -$110K 0.26% 86
2024
Q1 		$625K Hold
1,494
– – 0.24% 97
2023
Q4 		$608K Sell
1,494
-2
-0.1% -$739 0.26% 89
2023
Q3 		$520K Sell
1,496
-321
-18% -$112K 0.25% 86
2023
Q2 		$639K Buy
1,817
+123
+7% +$41.4K 0.24% 102
2023
Q1 		$534K Sell
1,694
-95
-5% -$28.5K 0.22% 120
2022
Q4 		$517K Buy
1,789
+56
+3% +$17.1K 0.23% 118
2022
Q3 		$502K Hold
1,733
– – 0.24% 90
2022
Q2 		$488K Sell
1,733
-75
-4% -$20.1K 0.22% 100
2022
Q1 		$472K Sell
1,808
-757
-30% -$180K 0.15% 141
2021
Q4 		$563K Buy
2,565
+159
+7% +$30.9K 0.15% 158
2021
Q3 		$436K Sell
2,406
-352
-13% -$68.7K 0.13% 176
2021
Q2 		$556K Hold
2,758
– – 0.14% 163
2021
Q1 		$593K Sell
2,758
-28,589
-91% -$6.28M 0.16% 147
2020
Q4 		$7.41M Hold
31,347
– – 0.37% 68
2020
Q3 		$8.53M Buy
31,347
+1,788
+6% +$493K 0.47% 50
2020
Q2 		$8.58M Buy
29,559
+13,398
+83% +$3.63M 0.52% 40
2020
Q1 		$3.85M Buy
16,161
+648
+4% +$149K 0.28% 86
2019
Q4 		$3.4M Hold
15,513
– – 0.2% 129
2019
Q3 		$2.63M Hold
15,513
– – 0.17% 157
2019
Q2 		$2.85M Buy
15,513
+609
+4% +$106K 0.19% 135
2019
Q1 		$2.74M Sell
14,904
-1,323
-8% -$244K 0.19% 134
2018
Q4 		$2.69M Sell
16,227
-425
-3% -$73.6K 0.19% 136
2018
Q3 		$3.21M Hold
16,652
– – 0.2% 134
2018
Q2 		$2.83M Sell
16,652
-1,267
-7% -$196K 0.18% 148
2018
Q1 		$2.92M Sell
17,919
-1,718
-9% -$281K 0.18% 146
2017
Q4 		$2.94M Hold
19,637
– – 0.16% 159
2017
Q3 		$2.99M Buy
19,637
+1,034
+6% +$156K 0.11% 162
2017
Q2 		$2.4M Buy
18,603
+1,732
+10% +$208K 0.09% 184
2017
Q1 		$1.84M Sell
16,871
-1,953
-10% -$172K 0.08% 217
2016
Q4 		$1.39M Hold
18,824
– – 0.06% 257
2016
Q3 		$1.64M Buy
18,824
+395
+2% +$37.3K 0.07% 236
2016
Q2 		$1.58M Hold
18,429
– – 0.07% 230
2016
Q1 		$1.47M Hold
18,429
– – 0.07% 228
2015
Q4 		$2.32M Buy
18,429
+160
+0.9% +$19.3K 0.11% 153
2015
Q3 		$1.9M Buy
18,269
+764
+4% +$98.2K 0.09% 166
2015
Q2 		$2.16M Buy
17,505
+670
+4% +$84.4K 0.1% 161
2015
Q1 		$1.99M Buy
16,835
+6,400
+61% +$767K 0.09% 170
2014
Q4 		$1.24M Hold
10,435
– – 0.06% 222
2014
Q3 		$1.17M Hold
10,435
– – 0.06% 224
2014
Q2 		$988K Buy
10,435
+3,435
+49% +$241K 0.05% 263
2014
Q1 		$495K Hold
7,000
– – 0.03% 412
2013
Q4 		$520K Buy
+7,000
New +$487K 0.03% 403

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Sentry Investment Management's VRTX Position: Q1 2026 in Review

Sentry Investment Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 640 shares — an estimated $290K sold.

Sentry Investment Management first reported a position in VRTX in Q4 2013 and held it in 49 quarters. The position peaked at $8.58M in Q2 2020. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Sentry Investment Management reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Sentry Investment Management sold 640 Vertex Pharmaceuticals shares in Q1 2026, an estimated $290K.
  • Sentry Investment Management first reported a position in Vertex Pharmaceuticals in Q4 2013 and held it in 49 quarters.
  • Sentry Investment Management's Vertex Pharmaceuticals position peaked at $8.58M in Q2 2020.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Sentry Investment Management's 13F filing for Q1 2026, filed 8 May 2026.